Deferasirox (Exjade®) for the treatment of chronic iron overload due to blood transfusions

All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000443
English
Authors' recommendations: Deferasirox (Exjade®..) is recommended for use within NHS Wales for the treatment of chronic iron overload due to frequent blood transfusions ( 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. It is also recommended for the treatment of chronic iron overload due to blood transfusions when desferrioxamine (DFO) therapy is contraindicated or inadequate in the following patient groups: - in patients with other anaemias, - in patients aged 2 to 5 years, - in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells). Deferasirox (Exjade®) is not suitable for shared care within NHS Wales.
Details
Project Status: Completed
Year Published: 2008
URL for published report: http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&amp;id=100590&amp;pid=24773
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Deferoxamine
  • Iron Chelating Agents
  • Blood Transfusion
  • Iron Overload
  • Triazoles
Contact
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.